In plain English
Late-Onset Alzheimer's Disease (ICD-11 6D80.1) is by far the most common form of dementia, with symptoms beginning from age 65. It accounts for around 60 per cent of dementia in older adults. The course is gradual, treatment is well-established, and lifestyle measures matter at every stage.
What Late-Onset Alzheimer's Disease is
Late-Onset Alzheimer's Disease is Alzheimer's Disease with symptom onset from age 65 onwards. It is the typical clinical picture most people associate with "Alzheimer's": insidious short-term memory loss, gradually progressing over years, with later involvement of language, executive function and visuospatial skill. Around one in six people over 80 has Alzheimer's Disease in some form.
How it presents
The classic presentation involves:
- Forgetting recent conversations, repeating questions, misplacing items;
- Difficulty with new information (a new phone, a new route);
- Word-finding difficulty and reduced fluency;
- Mild navigation errors in unfamiliar places;
- Modest difficulty with complex tasks (finances, planning a trip).
Family typically notice changes before the person themselves. Memory remains the most affected domain throughout, with relatively preserved older memories until later stages.
Risk factors
Modifiable risk factors identified by the 2024 Lancet Commission include Hypertension, hearing loss, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol, traumatic brain injury, air pollution, social isolation, less education, low LDL cholesterol management, and visual impairment. Genetic factors play a role, particularly APOE4, although unlike Early-Onset Alzheimer's Disease, single-gene mutations are rare.
How it is diagnosed
Standard memory clinic work-up applies: history (with collateral), ACE-III, blood tests, ECG, structural Magnetic Resonance Imaging. The typical MRI finding is medial temporal lobe atrophy (Scheltens MTA grade 1 to 3). NICE NG97 1.2.17 emphasises that Alzheimer's Disease should not be ruled out on imaging alone; around one in six clinically diagnosed cases has an unremarkable structural scan.
Treatment
Cholinesterase Inhibitors are licensed for mild to moderate disease under NICE TA217. Memantine is added or substituted for moderate to severe disease. About 60 per cent of people who tolerate Cholinesterase Inhibitors experience meaningful improvement in attention, memory and daily function.
Cognitive Stimulation Therapy is the non-pharmacological treatment with the strongest evidence in mild to moderate disease and is recommended by NICE. Anti-amyloid antibody therapies (Lecanemab, Donanemab) are not currently recommended for routine NHS use; see Lecanemab and Donanemab.
Course
Average life expectancy from clinical diagnosis is around 8 to 10 years, with wide variation. Factors associated with slower progression include early diagnosis, treatment adherence, good vascular health, regular physical and cognitive activity, social engagement, and a supportive carer.
Practical priorities
- Lasting Power of Attorney for health and finance while capacity is intact;
- Vascular risk reduction with the GP;
- Notification of the DVLA;
- Connection with the Alzheimer's Society and a local Memory Cafe;
- Adherence to medication if prescribed, with three-month review;
- Active lifestyle: 150 minutes of moderate exercise a week, Mediterranean-style eating, regular social contact.
Frequently asked questions
Is Late-Onset Alzheimer's the same as 'old age forgetfulness'?
No. Normal age-related forgetting is mild and does not interfere with daily independence. Alzheimer's Disease is more frequent, more disruptive, and progressive.
How long will I live with Late-Onset Alzheimer's?
Average life expectancy from diagnosis is 8 to 10 years, with substantial variation. Earlier diagnosis, treatment adherence, vascular control, exercise and social engagement are associated with longer trajectories.
Will the medication cure it?
No. Cholinesterase Inhibitors and Memantine help symptoms; they do not stop the underlying disease. Anti-amyloid antibodies modestly slow decline in early disease but are not currently available on the NHS.
Does APOE4 mean I will get Alzheimer's?
APOE4 increases risk but does not determine outcome. Many people with APOE4 do not develop Alzheimer's Disease; many people without APOE4 do. Lifestyle modifies risk regardless.
Should I still be active?
Yes. Regular physical activity, social engagement and cognitive stimulation slow progression and improve quality of life at every stage.
References
- World Health Organization. ICD-11 6D80.1.
- NICE TA217 and NG97.
- Livingston G et al. 2024 Lancet Commission.
- McKhann GM et al. NIA-AA criteria. Alzheimer's and Dementia 2011.